---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ANX007-GLA-02"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ANX007-GLA-02. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 30 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence/anx007-gla-02"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ANX007-GLA-02

<a id="heading-3.1.4"></a>

## 3.1.4 ANX007-GLA-02

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Registered primary, secondary, and exploratory objectives of the phase 1b study

> “The primary objective is to evaluate the safety and tolerability of repeat IVT injections of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the anterior chamber fluid pharmacokinetics (PK) of ANX007, PD effect of ANX007 on anterior chamber fluid C1q activity, and immunogenicity. An exploratory objective will evaluate ocular PD effect of ANX007.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.1-2"></a>

#### Published objective of the repeat-dose study

> “The phase Ib study was a double-masked, randomized, sham-controlled trial evaluating 2 dose levels of ANX007 (2.5 mg and 5 mg) to determine the safety and tolerability (primary objectives) of 2 repeat monthly IVT injections (NCT04188015).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Registry dates for the phase 1b study

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2018-07-25” |
| Primary completion (actual) | “2019-06-03” |
| Study completion (actual) | “2019-06-03” |

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.2-2"></a>

#### Phase 1b study sites

> “The phase Ib study was conducted at 2 sites in the United States.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “Eye Research Foundation”
> “Stanford Health Care”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Registered design of the phase 1b study

> “A Phase 1b, Randomized, Double-masked, Sham-controlled Study of ANX007 Administered as Intravitreal Injections to Assess Safety and Tolerability in Participants With Primary Open-angle Glaucoma”
> “This is a phase 1b, double-masked, sham-controlled study evaluating 2 dose levels of ANX007 administered as 2 IVT injections separated by 4 weeks.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.3-2"></a>

#### Published design of the two glaucoma studies

> “An open-label, single-dose-escalation phase Ia study followed by a double-masked, randomized, sham-controlled, repeat-injection phase Ib study.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Published inclusion criteria for the phase 1b study

> “In the phase Ib study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma with a mean deviation of −3 to −24 decibels (dB) on a reliable visual field test using the Humphrey field analyzer in the study eye as determined at screening, and an IOP < 21 mm Hg at screening and day 1, with no change to the IOP treatment regimen anticipated throughout study participation.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.4-2"></a>

#### Registered exclusion criteria for the phase 1b study

> “Extensive glaucomatous visual-field damage with a mean deviation worse than -18 dB on Humphrey visual field testing.”
> “Any current or prior ocular pathology, other than glaucoma, which could interfere with the conduct of the study including, but not limited to, retinal or optic nerve disease and media opacity in the study eye.”
> “Concurrent use of glucocorticoid medications administered by any ocular or systemic route.”
> “Previous treatment with another humanized monoclonal antibody, Fab or Fab'2.”
> “History of any autoimmune or neurologic disease.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Repeat-dose randomization and injection volumes

> “In the repeat-dose phase Ib study, patients were randomized to receive 2 injections 4 weeks apart (day 1 and day 29) of sham (no ocular penetration) or 2.5 mg ANX007 or 5.0 mg ANX007. Doses were administered at volumes of 20 μL (1 mg dose), 50 μL (2.5 mg dose), and 100 μL (5 mg dose), respectively.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.5-2"></a>

#### Sham procedure

> “For the sham injection, the preparation was identical to injection with ANX007. The sham injection was performed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of an empty syringe without a needle.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.5-3"></a>

#### Registered phase 1b arms

| Arm | Registry description |
| --- | --- |
| 2.5 mg ANX007 | “A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.” |
| 5.0 mg ANX007 | “A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.” |
| Sham procedure | “1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.” |

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Registered primary and secondary outcomes of the phase 1b study

| Outcome | Time frame |
| --- | --- |
| “To evaluate the safety and tolerability of ANX007 in participants with primary open-angle glaucoma as measured by occurrence of treatment-emergent adverse events.” | “Day 85” |
| “Evaluate PK parameters of ANX007 in aqueous humor after repeat intravitreal injections” | “Day 29” |
| “Evaluate PD parameters of ANX007 in aqueous humor after repeat intravitreal injections” | “Day 29” |
| “Evaluate PD parameters of ANX007 in serum after repeat intravitreal injections” | “Day 29” |
| “Immunogenicity of ANX007 as measured by serum anti-drug antibodies (ADA) after repeat intravitreal injections of ANX007” | “Day 84” |

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.6.1-2"></a>

##### Safety assessments and follow-up in the phase 1b study

> “In the repeat-dose phase Ib study, patients were followed for a total of 12 weeks for safety, tolerability, PK (unbound ANX007 concentration in serum and aqueous humor)”
> “The safety assessments included AEs, vital signs, physical examination, urinalysis, complete blood count, serum chemistries, best corrected visual acuity assessment, slit-lamp examination, IOP measurement, and dilated fundoscopy.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.6.1-3"></a>

##### Aqueous humor C1q as a measure of retinal target engagement

> “Inhibition of C1q in the aqueous humor is anticipated to represent inhibition of C1q in relevant sites of neurodegenerative ophthalmic disease within the retina.”
> “In these animal studies, complete C1q target engagement in the aqueous humor reflected complete target engagement in the vitreous and retinal tissue, with measurable unbound drug at these sites in the back of the eye (Annexon, data on file).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “These patients had aqueous humor taps so that ocular fluid could be analyzed for levels of vonaprument and free C1q”
> “immediately prior to first dose (day 1) and prior to second dose (day 29).”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.4.6.1-4"></a>

##### Aqueous humor sampling and assays

> “Aqueous humor was collected only in the phase Ib study per investigator standard of care into a tube provided for the study.”
> “Plate-captured C1q was detected using a monoclonal mouse anti-C1q antibody-alkaline phosphatase conjugate that binds to the same site as ANX007, thus enabling measurement of free C1q levels.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned and enrolled participants in the phase 1b study

> “Approximately 15-29 subjects will be enrolled. An interim analysis of the initial set of 15 participants may be conducted. Based on this analysis, an additional 10-14 participants may be enrolled at a 1:1 ratio to receive one of the two dose levels.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

> “Seventeen patients (mean Humphrey visual field deviation between −3 and −24 dB) were enrolled in phase Ib and randomized to 2 monthly doses of ANX007 (sham, n = 6; 2.5 mg ANX007, n = 6; or 5 mg ANX007, n = 5).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Descriptive analysis without hypothesis testing

> “No formal comparisons or hypothesis testing were planned for comparisons between dosing levels evaluated in either study, and data are presented descriptively throughout. Descriptive statistics for categorical variables included counts and percentages. Descriptive statistics for continuous variables included means, medians, standard deviation (SD), and minimum and maximum values.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Treated participants and early terminations in the phase 1b study

> “In the phase Ib study, 18 patients were included in the study and 17 received study treatment. One patient was randomized to receive ANX007 2.5 mg but terminated participation in the study and did not receive any study treatment due to elevated IOP on day 1.”
> “One patient with pseudo-exfoliative glaucoma in the sham group terminated the study early after receiving the day 1 injection due to protocol violation (pseudo-exfoliation glaucoma was not recognized as included in primary open angle glaucoma inclusion criteria).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Demographics of the phase 1b study by arm

| Characteristic | Sham (n = 6) | ANX007 2.5 mg (n = 6) | ANX007 5.0 mg (n = 5) | Overall (n = 17) |
| --- | --- | --- | --- | --- |
| Age, mean (SD), yr | “70.2 (22.8)” | “60.3 (16.2)” | “74.0 (8.0)” | “67.8 (17.2)” |
| Age, median (min, max), yr | “79.5 (24, 82)” | “58.5 (35, 78)” | “74.0 (65, 86)” | “75.0 (24, 86)” |
| Male, n (%) | “4 (66.7)” | “2 (33.3)” | “2 (40.0)” | “8 (47.1)” |
| Female, n (%) | “2 (33.3)” | “4 (66.7)” | “3 (60.0)” | “9 (52.9)” |
| Black/African American, n (%) | “0” | “1 (16.7)” | “0” | “1 (5.9)” |
| Asian, n (%) | “1 (16.7)” | “1 (16.7)” | “1 (20.0)” | “3 (17.6)” |
| White, n (%) | “5 (83.3)” | “4 (66.7)” | “4 (80.0)” | “13 (76.5)” |
| Weight, mean (SD), kg | “74.8 (20.3)” | “79.7 (10.1)” | “88.4 (15.0)” | “80.5 (15.8)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.2-2"></a>

##### Overall phase 1b study population

> “The majority of patients were female (n = 9, 52.9%) and White (n = 13, 76.5%), with a mean age (SD) of 67.8 (17.2) years (Table 1).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Aqueous humor C1q target engagement at day 29

> “Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups. Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects (Fig 4).”
> “Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “achieved complete suppression of C1q at 2.5 mg and 5 mg.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

> “Patient aqueous humor PK/PD supports 5mg at least monthly intravitreal injection”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.4.8.3-2"></a>

##### Aqueous humor drug concentrations at day 29

> “Mean (SD) and median (min, max) ANX007 levels in aqueous humor on day 29 were 911 ng/ml (846) and 631 (225, 2539) ng/ml in the ANX007 2.5 mg dose group and 5345 ng/ml (6351) and 3111 (413, 12 512) ng/ml in the ANX007 5.0 mg dose group (Fig 3).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.3-3"></a>

##### Systemic pharmacokinetics and pharmacodynamics after repeat dosing

> “The PK and PD analyses conducted in the phase 1b study demonstrated detectable levels of ANX007 and corresponding complete reduction of free C1q in the aqueous humor following IVT injection with ANX007 at both the 2.5 and 5.0 mg dose levels through 29 days after the first injection. Importantly, no PK or PD changes were observed in the systemic circulation.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Adverse events in the phase 1b study by arm

| n (%) | Sham (n = 6) | ANX007 2.5 mg (n = 7) | ANX007 5 mg (n = 5) | Overall (n = 18) |
| --- | --- | --- | --- | --- |
| Any TEAE | “2 (33.3)” | “2 (33.3)” | “2 (40.0)” | “6 (33.3)” |
| Ocular disorders | “2 (33.3)” | “2 (33.3)” | “2 (40.0)” | “6 (33.3)” |
| Infection | “0” | “1 (16.7)” | “0” | “1 (5.5)” |
| Injury | “0” | “1 (16.7)” | “0” | “1 (5.5)” |
| Treatment-related TEAE | “2 (33.3)” | “1 (16.7)” | “2 (40.0)” | “5 (27.8)” |
| Conjunctival hemorrhage | “0” | “0” | “1 (20.0)” | “1 (5.5)” |
| Conjunctival hyperemia | “0” | “1 (16.7)” | “0” | “1 (5.5)” |
| Eye irritation | “1 (16.7)” | “0” | “1 (20.0)” | “2 (11.1)” |
| Foreign body sensation in eyes | “1 (16.7)” | “0” | “0” | “1 (5.5)” |
| Ocular hyperemia | “1 (16.7)” | “0” | “0” | “1 (5.5)” |
| Vision blurred | “1 (16.7)” | “0” | “0” | “1 (5.5)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-2"></a>

##### Serious, severe, and treatment-emergent adverse events after repeat dosing

> “No serious AEs, severe TEAEs, or fatal AEs were reported in any group at any time during the study. A total of 6 TEAEs were reported, 2 events in each dose level. Treatment-emergent AEs included conjunctival hemorrhage, conjunctival hyperemia, eye irritation/pain, foreign body sensation in the eyes, ocular hyperemia, blurry vision, and 1 systemic TEAE of bronchitis, which was not assessed to be related to ANX007 (Table 2). All TEAEs were mild in severity and none resulted in study discontinuation. All resolved by study closure. No drug-specific safety signals were observed, and there were no clinically significant laboratory results during study.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-3"></a>

##### Intraocular pressure after repeat dosing

> “Intraocular pressure returned to normal levels (≤ 21 mm Hg) within 45 minutes for all patients and within 30 minutes for 16/17 (94.1%) patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-4"></a>

##### Best corrected visual acuity through day 84

> “Between baseline and day 84, the mean (SD) logarithm of the minimum angle of resolution results for the study eye decreased (representing improved visual acuity) in the Sham (−0.073 ± 0.0485) and ANX007 2.5 mg (−0.032 ± 0.1001) groups but increased (representing worsened visual acuity) in the ANX007 5.0 mg group (0.024 ± 0.0485) (Fig 2).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-5"></a>

##### Anti-drug antibodies after repeat dosing

> “Low levels of ADA positivity were detected in 7 patients (1 patient in the sham group, 3 patients in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group). The signal in the ADA assay was marginally above the cut points. Of these, 5 patients (1 patient in the sham group, 1 patient in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group) were ADA-positive at all time points, including the predosing period, without any dose-related changes.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary: glaucoma population, small sample, and short follow-up

ANX007-GLA-02 enrolled participants with primary open-angle glaucoma, a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. Seventeen participants received study treatment (sham, 6; 2.5 mg, 6; 5 mg, 5), follow-up lasted 12 weeks with 2 injections given 4 weeks apart, and no formal comparisons or hypothesis testing were planned, so the results are descriptive. The safety table lists 7 participants in the 2.5-mg column and 18 overall, while the text reports 6 participants treated with 2.5 mg and 17 treated overall. Target engagement was measured in aqueous humor, which the authors state is “anticipated to represent” inhibition of C1q in the retina, supported by nonhuman primate data on file. The 5-mg dose was given in 100 μL in this study, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose. Low-level anti-drug antibody positivity was detected in 7 participants, including 1 in the sham group, which the authors attribute to likely false positives in the assay.

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.4.9-2"></a>

#### Author-stated limitations of the phase 1b study

> “When considering the results of these data in a broader context, it should be noted that the relatively small sample size and descriptive nature of the analyses preclude formal clinical endpoint comparisons between the sham and treatment groups in the phase Ib study and also between the dose levels evaluated. Additional data from larger cohorts will add to our understanding of safety and efficacy at different dosing levels.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
